First pharmaceutical company leader in the UAE and the Middle East and North Africa (MENA)
JULPHAR has a diversified portfolio of quality generic medicine covering all major therapeutic areas (endocrinology, anti-infectives, cardiology, gastroenterology, OTC, nephrology, dermatology, pulmonology, metabolic gynecology).
JULPHAR employs staff and achieved in 2013 a turnover of € 272 million
The partnership was recently  concluded by the introduction of JULPHAR into the capital of IBERAL (SAIDAL subsidiary). The production unit is partially achieved.